Armata Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $9.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the promising potential of Armata Pharmaceuticals’ AP-SA02 treatment. The recent data from the Phase 2a diSArm study presented at IDWeek 2025 demonstrated significant clinical efficacy of AP-SA02 in treating complicated S. aureus bacteremia. The study results showed a high responder rate for AP-SA02, with an 88% test of cure rate compared to 58% for the best available antibiotic therapy alone, indicating a strong therapeutic benefit.
Moreover, the engineered diversity within AP-SA02, which includes multiple genetically stable and reproducible phage variants, enhances its broad and targeted antibacterial activity. This strategic design allows for a tailored approach to match the right phage variant to the specific bacterial strain in each patient, thereby increasing the likelihood of successful treatment outcomes. These compelling findings support the advancement of AP-SA02 into a pivotal Phase 3 trial, scheduled for 2026, further reinforcing the positive outlook on Armata Pharmaceuticals’ stock.